250 related articles for article (PubMed ID: 7673616)
1. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
Takeda H; Hokari K; Asaka M
J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
[TBL] [Abstract][Full Text] [Related]
2. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
Shirai N; Furuta T; Xiao F; Kajimura M; Hanai H; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
[TBL] [Abstract][Full Text] [Related]
3. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
Sakaguchi M; Ashida K; Umegaki E; Miyoshi H; Katsu K
J Clin Gastroenterol; 1995; 20 Suppl 2():S27-31. PubMed ID: 7594334
[TBL] [Abstract][Full Text] [Related]
4. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Katz PO; Hatlebakk JG; Castell DO
Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
[TBL] [Abstract][Full Text] [Related]
5. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
[TBL] [Abstract][Full Text] [Related]
6. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects.
Geus WP; Mulder PG; Nicolai JJ; Van den Boomgaard DM; Lamers CB
Aliment Pharmacol Ther; 1998 Apr; 12(4):329-35. PubMed ID: 9690721
[TBL] [Abstract][Full Text] [Related]
7. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.
Bell NJ; Hunt RH
Aliment Pharmacol Ther; 1996 Dec; 10(6):897-904. PubMed ID: 8971286
[TBL] [Abstract][Full Text] [Related]
8. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
9. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
[TBL] [Abstract][Full Text] [Related]
10. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
11. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects.
Fraser AG; Sawyerr AM; Hudson M; Smith MS; Pounder RE
Aliment Pharmacol Ther; 1996 Aug; 10(4):523-7. PubMed ID: 8853755
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.
Bruley des Varannes S; Levy P; Lartigue S; Dellatolas F; Lemaire M; Galmiche JP
Aliment Pharmacol Ther; 1994 Jun; 8(3):309-14. PubMed ID: 7918926
[TBL] [Abstract][Full Text] [Related]
13. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Huang JQ; Goldwater DR; Thomson AB; Appelman SA; Sridhar S; James CF; Chiu YL; Pilmer BL; Keith RG; Hunt RH
Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
[TBL] [Abstract][Full Text] [Related]
14. Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring.
Sugiyama M; Aoki T; Matsuo Y
J Clin Gastroenterol; 1995; 20 Suppl 2():S14-6. PubMed ID: 7594331
[TBL] [Abstract][Full Text] [Related]
15. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers.
Verdú EF; Fraser R; Armstrong D; Blum AL
Scand J Gastroenterol; 1994 Dec; 29(12):1065-9. PubMed ID: 7886393
[TBL] [Abstract][Full Text] [Related]
16. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration.
Brummer RJ; Geerling BJ; Stockbrügger RW
Dig Dis Sci; 1997 Oct; 42(10):2132-7. PubMed ID: 9365148
[TBL] [Abstract][Full Text] [Related]
17. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Tazuma S; Horikawa Y; Nakamura M
Dig Dis Sci; 2005 Jul; 50(7):1202-6. PubMed ID: 16047460
[TBL] [Abstract][Full Text] [Related]
18. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
19. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
Nagaya H; Inatomi N; Satoh H
Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
[TBL] [Abstract][Full Text] [Related]
20. [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Inatomi N; Murakami I; Asano S; Inada I; Satoh H
Nihon Yakurigaku Zasshi; 1996 Dec; 108(6):333-43. PubMed ID: 9017687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
